期刊文献+

培美曲塞单药或联合奈达铂治疗对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌 被引量:5

Pemetrexed alone or in combination with nedaplatin in recurrence and carboplatin/paclitaxel resistance advanced epithelial ovarian carcinoma
原文传递
导出
摘要 目的观察培美曲塞单药或联合奈达铂治疗对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌的疗效和不良反应。方法将对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌50例随机分为A、B两组,A组第1天给予培美曲塞500m g/m2,每21天重复;B组第1天给予培美曲塞500m g/m2、奈达铂80m g/m2,每21天重复;直到疾病恶化为止。结果两组均无完全缓解病例,部分缓解A组4例、B组11例,稳定A组15例、B组11例,病情恶化A组6例、B组3例,总有效率A组16.0%、B组44.0%,差异有统计学意义(2χ=4.667,P=0.031)。中位肿瘤恶化时间A组2.4个月,B组3.6个月(P=0.046)。中位生存期A组6.0个月,B组7.5个月(Log-rank,P=0.048)。不良反应主要是骨髓抑制。结论培美曲塞单药或联合奈达铂治疗对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌均有效,培美曲塞联合奈达铂总有效率、中位肿瘤恶化时间及中位生存期均明显好于培美曲塞单药,骨髓抑制较明显,但可以耐受。 Objective To observe the efficacy and side effect of pemetrexed(PEM) alone or in combination with nedaplatin(NDP) in recurrence and carboplatin(CBP) and paclitaxel(PTX) resistance advanced epithelial ovarian carcinoma.Methods Fifty patients with recurrence and CBP and PTX resistance advanced epithelial ovarian carcinoma were randomly divided into groups A and B. Twenty-five patients in group A were treated only with PEM 500 mg/m^2 on day 1 which was repeated every 21 days, and twenty-five patients in group B were treated with PEM 500 mg/m^2,and NDP 80 g/m^2 on day 1 which was repeated every 21 days, until disease had progressed.Results No patients achieved complete response(CR) in either group but 4 patients in group A(or 11 patients in group B) achieved a partial response(PR) and 15 patients in group A(or 11 patients in group B) achieved a stable disease(SD) and the overall response rate(ORR) was 16.0% in group A and 44.0% in group B(χ^2=4.667,P=0.031). The median time to progression(mTTP) was respectively 2.4 months in group A and 3.6 months in group B(P=0.046) and the median survival(mS) was 6.0 months in group A and 7.5 months in group B(Log-rank, P=0.048) .The major adverse effect was marrow depression. Conclusions PEM alone or in combination with NDP were effective for recurrence and CBP/PTX resistance in advanced epithelial ovarian carcinoma.The ORR, mTTP and mS of PEM in combination with NDP was significantly better than PEM alone and marrow depression was marked,but tolerated.
出处 《山东大学学报(医学版)》 CAS 北大核心 2011年第5期122-124,共3页 Journal of Shandong University:Health Sciences
关键词 卵巢肿瘤 药物疗法 培美曲塞 奈达铂 治疗结果 Ovarian neoplasms; Medical treatment; Pemetrexed; Nedaplatin; Treatment outcome
  • 相关文献

参考文献8

  • 1Therasse P, Aibuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 92(3) :205-216.
  • 2Tomao F, Panici P B, Frail L, et al. Emerging role of pemetrexed in ovarian cancer [ J ]. Expert Rev Anticancer Ther, 2009, 9(12):1727-1735.
  • 3Miller D S, Blessing J A, Krasner C N, et al. Phase Ⅱ e- valuation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group [J]. J Clin Oncol, 2009, 27(16) :2686-2691.
  • 4Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase Ⅱ study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer [ J ]. Eur J Cancer, 2009, 45 ( 8 ) : 1415-1423.
  • 5Koshiyama M, Kinezaki M, Uchida T, et al. Chemosen- sitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a compar- ison with cisplatin E J ]. Anticancer Res, 2005, 25 ( 6C ) : 4499-4502.
  • 6Goto T, Takano M, Ohishi R, et al. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-re- sistant/refractory epithelial ovarian, tubal and peritoneal cancers[ J ]. J Obstet Gynaecol Res, 2010, 36 (4) : 764- 768.
  • 7Sehouli J, Camara O, Mahner S, et al. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer [J]. Cancer Chemother Pharmacol, 2010, 66 ( 5 ) : 861- 868.
  • 8Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemo- therapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group[J]. Ann Oncol, 2010, 21 ( 1 ) :61-66.

同被引文献56

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2符淳,李光仪,刘晓英,林秋华,刘风英,谢咏.顺铂诱导卵巢癌耐药细胞系A2780/DDP凋亡的时间和剂量依从性[J].肿瘤防治研究,2006,33(8):561-564. 被引量:9
  • 3王华,王秀美,叶丽华,贡丽霞,韦溶澄.多西紫杉醇联合奈达铂治疗复发卵巢上皮癌临床研究[J].山东医药,2007,47(13):62-62. 被引量:6
  • 4Jemal A, Siegel R, Xu J, et al. Cancer statistics,2010 [ J ]. CA : A Cancer Journal for Clinicians,2010,60(5) :277-300.
  • 5Eisenhaner EA,'Ilaerasse P,Bogaerts J,et al. New response evaluation criteria in solid turnouts :revised RECIST guideline( version 1.1 ) [J]. Eurow-zm Journal of Cancer,2009,45(2) :228-247.
  • 6Roth AD,Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer[J]. Annals of Oncology,2003,14:ii41-ii44.
  • 7McKeage MJ. Lobaplatin: a new antitumour platinum drug [ J ]. Expert Opinion on Investigational Drugs,2001,10( 1 ) :119-128.
  • 8Xie CY, Xu YP, Jin W, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer[ J]. Anti-Cancer Drugs,2012,23 (7) :698-705.
  • 9Engel JB, Martens T, Hahne JC, et al. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro [ J ]. Anti- Cancer Drugs,2012,23(4) :426-436.
  • 10Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation [ J ]. Journal of Vascular and Interventional Radiology,2010,21 (3) :333-338.

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部